The role of ethylenediamine tetraacetic acid (EDTA) as in vitro anticoagulant for diagnostic purposes

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 5, 2007, Pages 565-576

  Banfi, Giuseppe ^a,c,d   Salvagno, Gian Luca ^b,c   Lippi, Giuseppe ^b,c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c SIMEL (Italian Society of Laboratory Medicine)   (Italy)

^d IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

Author keywords

Anticoagulants; Blood; Laboratory testing; Plasma; Serum

Indexed keywords

AMINO ACID; BIOLOGICAL MARKER; CALCIUM; CYTOKINE; DRUG; EDETIC ACID; HIRUDIN; METAL ION; PEPTIDE; PROTEIN; THROMBIN INHIBITOR; VITAMIN;

ANTICOAGULATION; BLOOD CELL; BLOOD CLOTTING; BLOOD EXAMINATION; BLOOD GROUP ABO SYSTEM; CELL STRUCTURE; CLINICAL CHEMISTRY; DIAGNOSTIC PROCEDURE; ENZYME MECHANISM; ERYTHROCYTE; HEMATOLOGICAL PARAMETERS; HORMONE DETERMINATION; INFECTION; LABORATORY TEST; LEUKOCYTE; MEASUREMENT; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEOMICS; REVIEW; THROMBOCYTE; VIROLOGY;

ANTICOAGULANTS; BLOOD CELLS; EDETIC ACID; HEMATOLOGIC TESTS; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES;

EID: 34248149071     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.110     Document Type: Review

References (142)

1. Perrotta G, Roberts L, Glazier J, Schumacher HR. Use of sodium citrate anticoagulant for routine haematological analysis on the CD4000: an opportunity to enhance efficiency in the clinical laboratory. Lab Hematol 1998;4:156-62.
2. Okada T. Development and problems of automated hematology analyzers. Sysmex J Int 1999;9:52-7.
3. International Council for Standardization in Haematology. Recommendations of the International Council for Standardization in Haematology for ethylenediamine tetraacetic acid anticoagulation of blood for blood cell counting and sizing: expert panel on cytometry. Am J Clin Pathol 1993;100:371-2.
4. Reardon DM, Warner B, Trowbridge EA. EDTA, the traditional anticoagulant of haematology: with increased automation is it time for review? Med Lab Sci 1991;48:72-5.
5. Narayanan S. Effect of anticoagulants used for blood collection on laboratory tests. Proc JCLA 1993;7:1-10.
6. National Committee for Clinical Laboratory Standards. H35-P. Additives to blood collection devices: EDTA. Proposed standard. Villanova, PA: NCCLS, 1989;9:851-74.
7. Dacie JV, Lewis SM. Practical haematology, 6th ed. Edinburgh: Churchill Livingstone, 1984:3.
8. 3EDTA: the anticoagulant of choice in routine haematology? Clin Lab Haematol 1991;13:291-5.
9. Felding P, Hyltoft Petersen P, Hørder M. The stability of blood, plasma and serum constituents during simulated transport. Scand J Clin Lab Invest 1981;41:35-40.
10. Kouri T, Siloaho M, Pohjavaara S, Koskinen P, Malminiemi O, Pohja-Nylander P, et al. Preanalytical factors and measurement uncertainty. Scand J Clin Invest 2005;65:463-76.
11. Guder WG, Ehret W, Fonseca-Wollheim F, Heil W, Muller-Plathe O, Schmitt Y, et al. The quality of diagnostic samples. Lab Med 2002;26:267-83.
12. Forum of European Societies of Clinical Chemistry (FESCC). The quality of diagnostic samples. Available at: http://www.diagnosticsample.com/. Accessed December 8, 2006.
13. Lippi G, Salvagno GL, Solero GP, Franchini M, Guidi GC. Stability of blood cell counts, hematologic parameters and reticulocytes indexes on the Advia A120 hematologic analyzer. J Lab Clin Med 2005;146:333-40.
14. National Committee for Clinical Laboratory Standard. Methods for reticulocyte counting (flow cytometry and supravital dyes); approved guideline. H44-A. Villanova, PA: NCCLS, 1997.
15. Cavill I, Kraaijenhagen R, Pradella R, D'Onofrio G, Herkner K, Rowan RM, et al. In vitro stability of the reticulocyte count. Clin Lab Haematol 1996;18:9-11.
16. Brugnara C, Colella GM, Cremins JC, Langley RC, Schneider TJ, Rutherford CR, et al. Effects of subcutaneous recombinant human erythropoietin in normal subjects: development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med 1994;123:660-7.
17. Banfi G, Dolci A. Preanalytical phase of sport biochemistry and haematology. J Sports Med Phys Fitness 2003;43:223-30.
18. Robinson N, Mangin P, Saugy M. Time and temperature dependant changes in red blood cell analytes used for testing recombinant erythropoietin abuse in sports. Clin Lab 2004;50:317-23.
19. Karpatkin S, Freedman ML. Hypersplenic thrombocytopenia differentiated from increased destruction by platelet volume. Ann Int Med 1978;89:200-3.
20. Bessman JD, Williams LJ, Gilmer PR. Platelet size in health and hematologic disease. Am J Clin Pathol 1982;78:150-3.
21. Lippi U, Schinella M, Modena M, Nicoli M. A new anticoagulant solution to stabilize platelet indices. Prog Med Lab 1989;3:111-5.
22. Trowbridge EA, Reardon DM, Hutchinson D, Pickering C. The routine measurement of platelet volume: a comparison of light scattering and aperture-impedance technologies. Clin Phys Physiol Meas 1985;6:221-38.
23. Reardon D, Hutchinson D, Bradley L, Trowbridge EA. Automated haematology: a comparative study of cell counting and sizing using aperture impedance and flow cytometric systems. Med Lab Sci 1987;44:320-5.
24. Thompson CB, Diaz DD, Quinn PG, Lapins M, Kurtz SR, Valeri CR. The role of anticoagulation in the measurement of platelet volumes. Am J Clin Pathol 1983;80:327-32.
25. Macey M, Azam U, McCarthy D, Webb L, Chapman ES, Okrongly D, et al. Evaluation of the anticoagulants EDTA and citrate, theophylline, adenosine, and dipyridamole (CTAD) for assessing platelet activation on the ADVIA 120 hematology system. Clin Chem 2002;48:891-9.
26. Banfi G. La pseudotrombocitopenia da EDTA. Biochim Clin 1987;11:957-62.
27. Lippi U, Schinella M, Biasioli B. Le pseudotrombocitopenie. Prog Med Lab 1991;5:81-8.
28. Payne BA, Pierre RV. Pseudothrombocytopenia: a laboratory artifact with potentially serious consequences. Mayo Clin Proc 1984;59:123-5.
29. Silvestri F, Masotti A, Pradella P, Zaja F, Barillari G, De Marco L. More on false thrombocytopenias: EDTA-dependent pseudothrombocytopenia associated with a congenital platelet release defect. Vox Sang 1996;71:27-9.
30. Savage RA. Pseudoleukocytosis due to EDTA-induced platelet clumping. Am J Clin Pathol 1984;81:317-22.
31. Mant MJ, Doery JC, Gauldie J, Sims H. Pseudothrombocytopenia due to platelet aggregation and degranulation in blood collected in EDTA. Scand J Hematol 1975;15:161-70.
32. Bartels PC, Schoorl M, Lombarts AJ. Screening for EDTA-dependent deviations in platelet counts and abnormalities in platelet distribution histograms in pseudothrombocytopenia. Scand J Clin Lab Invest 1997;57:629-36.
33. Vicari A, Banfi G, Bonini PA. EDTA-dependent pseudothrombocytopaenia: a 12-month epidemiological study. Scand J Clin Lab Invest 1988;48:537-42.
34. Mant MJ, Doery JC, Gauldie J, Sims H. Pseudothrombocytopenia due to platelet aggregation and degranulation in blood collected in EDTA. Scand J Hematol 1975;15:161-70.
35. Manthorpe R, Kofod B, Wiik A, Svehag SE. Pseudothrombocytopenia. In vitro studies on the underlying mechanism. Scand J Hematol 1981;26:385-90.
36. Silvestri F, Virgolini L, Savignano C, Zaja F, Velisig M, Baccarani M. Incidence and diagnosis of EDTA-dependent pseudothrombocytopenia in a consecutive outpatient population referred for isolated thrombocytopenia. Vox Sang 1995;68:35-9.
37. Pegels JG, Bruynes EC, Engelfriet CP, von dem Borne EG. Pseudothrombocytopenia: an immunologic study on platelet antibodies dependent on ethylene diamine tetraacetate. Blood 1982;59:157-61.
38. Onder O, Weinstein A, Hoyer LW. Pseudothrombocytopenia caused by platelet agglutinins that are reactive in blood anticoagulated with chelating agents. Blood 1980;56:1977-82.
39. Veenhoven WA, van der Schans GS, Huiges W, Metting-Scherpuis HE, Halie MR, Nieweg HO. Pseudothrombocytopenia due to agglutinins. Am J Clin Pathol 1979;72:1005-8.
40. Gschwandtner ME, Siostrzonek P, Bodinger C, Neunteufl T, Zauner C, Heinz G, et al. Documented sudden onset of pseudothrombocytopenia. Ann Hematol 1997;74:283-5.
41. Stiegler H, Fischer Y, Steiner S, Strauer BE, Reinauer H. Sudden onset of EDTA-dependent pseudothrombocytopenia after therapy with the glycoprotein IIb/IIIa antagonist c7E3 Fab. Ann Hematol 2000;79:161-4.
42. Yoshikawa T, Nakanishi K, Maruta T, Takenaka D, Hirota S, Matsumoto S, et al. Anticoagulant-induced pseudothrombocytopenia occurring after transcatheter arterial embolization for hepatocellular carcinoma. Jpn J Clin Oncol 2006;36:527-31.
43. Segura JJ, Calvo JR, Guerrero JM, Jimenez-Planas A, Sampedro C, Llamas R. EDTA inhibits in vitro substrate adherence capacity of macrophages: endodontic implications. J Endod 1997;23:205-8.
44. Grubb A, Nordin G. Notable steps in obtaining improved estimates for glomerular filtration rate. Clin Chem 2006;52:169-70.
45. Bernkop-Schnurch A, Scerbe-Saiko A. Synthesis and in vitro evaluation of chitosan-EDTA-protease inhibitor conjugates which might be useful in oral delivery of peptides and proteins. Pharm Res 1998;15:263-9.
46. Sakurai S, Shiojima I, Tanigawa T, Nakahara K. Aminoglycosides prevent and dissociate the aggregation of platelets in patients with EDTA-dependent pseudothrombocytopenia. Br J Haematol 1997;99:817-23.
47. Epstein HD, Kruskall MS. Spurious leukopenia due to in vitro granulocyte aggregation. Am J Clin Pathol 1988;89:652-5.
48. Hillyer CD, Knopf AN, Berkman EM. EDTA-dependent leukoagglutination. Am J Clin Pathol 1990;94:458-61.
49. Juneja S, Wolf M, McLennan R. Clumping of lymphoma cells in peripheral blood induced by EDTA. J Clin Pathol 1992;45:538-40.
50. Moraglio D, Banfi G, Arnelli A. Association of pseudothrombocytopenia and pseudoleukopenia: evidence for different pathogenic mechanisms. Scand J Clin Lab Invest 1994;54:257-65.
51. Pujol M, Ribera JM, Jimenez C, Ribera A, Abad E, Feliu E. Essential monoclonal gammopathy with an IgM paraprotein that is a cryoglobulin with cold agglutinin and EDTA-dependent platelet antibody properties. Br J Haematol 1998;100:603-4.
52. De Caterina M, Fratellanza G, Grimaldi E. Evidence of a cold immunoglobulin M autoantibody against 78-kD platelet glycoprotein in a case of EDTA-dependent pseudothrombocytopenia. Am J Clin Pathol 1993;99:163-7.
53. Beck ML, Freihaut B, Henry R, Pierce S, Bayer WL. A serum hemagglutinating property dependent upon polycarboxylic groups. Br J Hematol 1975;29:145-56.
54. Tedrow HE, Ziegler ZR. Evidence of anti-A1 inhibited by EDTA. Transfusion 1988;28:177-8.
55. Yasuda H, Ohto H, Motoki R, Uchikawa M. An EDTAassociated anti-B agglutinin: the role of ionized calcium. Transfusion 1997;37:1131-6.
56. Pewarchuk W, VanderBoom J, Blajchman MA. Pseudopolycythemia, pseudothrombocytopenia, and pseudoleukopenia due to overfilling of blood collection vacuum tubes. Arch Pathol Lab Med 1992;116:90-2.
57. Davis W. Abnormal platelet aggregation in elongated sample bottles. Clin Lab Haematol 1993;15:231-7.
58. Golanski J, Pietrucha T, Baj Z, Greger J, Watala C. Molecular insights into the anticoagulant-induced spontaneous activation of platelets in whole blood - various anticoagulants are not equal. Thromb Res 1996;83:199-216.
59. 2k M-protein. Clin Chim Acta 2000;299:119-28.
60. Macey MG, McCarthy DA, Davies C, Newland AC. The Q-Prep system: effects on the apparent expression of leucocyte cell surface antigens. Cytometry 1997;30:67-71.
61. Carter PH, Resto Ruiz S, Washington GC, Ethridge S, Palini A, Vogt R, et al. Flow cytometric analysis of whole blood lysis, three anticoagulants, and five cell preparations. Cytometry 1992;13:68-74.
62. Exley A, Cohen J. Optimal collection of blood samples for the measurement of tumor necrosis factor alpha. Cytokine 1990;2:353-6.
63. Riches P, Gooding R, Millar B, Rowbottom A. Influence of collection and separation of blood samples on plasma IL-1, IL-6 and TNFalpha concentrations. J Immunol Methods 1992;153:125-7.
64. Dugué B, Leppänen E, Gräsbeck R. Preanalytical factors and the measurement of cytokines in human subjects. Int J Clin Lab Res 1996;26:99-105.
65. De Jongh R. The influence of anticoagulation and timing of centrifugation on the measurement of blood proteins. In: Proceedings of the 2nd Symposium on Impact of the Preanalytical Phase, Oxford, UK, Jul 5-7, 1996:31-2.
66. Hoffmann JN, Hartl WH, Faist E, Jochum M, Inthron D. Tumor necrosis factor measurement and use of different anticoagulants: possible interference in plasma samples and supernatants from endotoxin-stimulated monocytes. Inflamm Res 1997;46:342-7.
67. Flower L, Ahuja RH, Humphries SE, Mohamed-Ali V. Effects of sample handling on the stability of interleukin 6, tumor necrosis factor alpha and leptin. Cytokine 2000;12:1712-6.
68. Engstad CS, Guttenberg TJ, Osterud B. Modulation of blood cell activation by four commonly used anticoagulants. Thromb Haemost 1997;77:690-6.
69. Brunialti MK, Kallas EG, Freudenberg M, Galanos C, Salomao R. Influence of EDTA and heparin on lipopolysaccharide binding and cell activation, evaluated at single-cell level in whole blood. Cytometry 2002;50:14-8.
70. Banfi G. State of art of preanalysis in laboratories in Italy performing endocrinological tests. Eur J Clin Chem Clin Biochem 1995;33:99-101.
71. Evans MJ, Livesey JH, Jane Ellis M, Yandle TG. Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones. Clin Biochem 2001;34:107-12.
72. Glendenning P, Laffer LL, Weber HK, Musk AA, Vasikaran SD. Parathyroid hormone is more stable in EDTA plasma than in serum. Clin Chem 2002;48:766-7.
73. Teal TK, Wood JL, Stevens PE, Lamb EJ. Stability of biointact (1-84) parathyroid hormone ex vivo in serum and EDTA plasma from hemodialysis patients. Clin Chem 2004;50:1713-4
74. Twomey PJ, Whitlock T, Pledger DR. Differences between serum and plasma for intact parathyroid hormone measurement in patients with chronic renal failure in routine clinical practice. J Clin Pathol 2005;58:1000-1.
75. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem 1991;37:1811-9.
76. Pandian MR, Morgan CH, Carlton E, Segre GV. Modified immunoradiometric assay of parathyroid hormone-related protein: clinical application in the differential diagnosis of hypercalcemia. Clin Chem 1992;38:282-8.
77. Durham BH, Robinson J, Fraser WD. Differences in the stability of intact osteocalcin in serum, lithium heparin plasma and EDTA plasma. Ann Clin Biochem 1995;32:422-3.
78. Banfi G, Daverio R. In vitro stability of osteocalcin. Clin Chem 1994;40:833-4.
79. Power MJ, O'Dwyer B, Breen E, Fottrell PF. Osteocalcin concentrations in plasma prepared with different anticoagulants. Clin Chem 1991;37:281-4.
80. Meisner M, Tschaikowsky K, Schnabel S, Schmidt J, Katalinic A, Schuttler J. Procalcitonin - influence of temperature, storage, anticoagulation and arterial or venous asservation of blood samples on procalcitonin concentrations. Eur J Clin Chem Clin Biochem 1997;35:597-601.
81. Berninger RW, Teixeira MF. a1-Antitrypsin: the effect of anticoagulants on the trypsin inhibitory capacity, concentration and phenotype. J Clin Chem Clin Biochem 1985;23:277-81.
82. Butler J. Negative interference in immunoassays. Clin Chem 1995;41:481-2.
83. Watkins J, Wild G, Smith S. Nafamostat to stabilize plasma samples taken for complement measurements. Lancet 1989;1:896-7.
84. Pfeifer PH, Kawahara MS, Hugli TE. Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. Clin Chem 1999;45:1190-9.
85. Bladbjerg EM, Overgaard K, Gram J, Jespersen J. The protein concentration of blood coagulation factor VII can be measured equally well in plasma and serum. Scand J Clin Lab Invest 1995;55:267-71.
86. Gleeson M, Kinlay S. Choice of anticoagulants affects measurement of plasma fibrinogen. Clin Chem 1993;39: 1754-5.
87. Banfi G. Präanalytik des prostata-spezifischen antigens. Lab Med 1998;22:87-9.
88. 1-antichymotrypsin in blood samples. Urology 1996;48:81-7.
89. Ulmert D, Becker C, Nilsson JA, Piironen T, Bjork T, Hugosson J, et al. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs. plasma after long-term storage at -20°C. Clin Chem 2006;52:235-9.
90. Jung K, Laube C, Lein M, Lichtinghagen R, Tscheche H, Schnorr D, et al. Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. Clin Chem 1998;44:1060-2.
91. Panteghini M, Altinier S, Dolci A, Pagani F, Pergolini P, Vernocchi A, et al. Multicenter evaluation of five methods for myoglobin determination. Clin Chem 1998;44:A121.
92. Dolci A. Preanalytical phase of cardiac markers. In: Proceedings of the 4th Expert Symposium "Biological and technical aspects of the preanalytical phase in clinical chemistry and laboratory medicine" Karlovy Vary, Czech Republic, Sept. 24-25, 1998.
93. Gerhardt W, Nordin G, Herbert AK, Burzell BL, Isaksson A, Gustavsson E, et al. Troponin T and I assays show decreases concentrations in heparin plasma compared with serum: lower recoveries in early than in late phases of myocardial injury. Clin Chem 2000;46:817-21.
94. Artner-Dworzak E, Lindner H, Puschendorf B. In vitro stability of human natriuretic peptide (h-ANP). Clin Chim Acta 1991;203:235-42.
95. Clerico A, Iervasi G, Del Chicca MG, Emdin M, Maffei S, Nannipieri M, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 1998;21:170-9.
96. Tsuji T, Imagawa K, Masuda H, Harikawa M, Shibata K, Kono M, et al. Stabilization of human brain natriuretic peptide in blood samples. Clin Chem 1994;40:672-3.
97. Dupuy AM, Terrier N, Dubois M, Boularan AM, Cristol JP. Heparin plasma sampling as an alternative to EDTA for BNP determination on the Access-Beckman Coulter - effect of storage at -20°C. Clin Lab 2006;52:393-7.
98. Numata Y, Dohi K, Furukawa A, Kikuoka S, Asada H, Fukunaga T, et al. Immunoradiometric assay for the N-terminal fragment of proatrial natriuretic peptide in human plasma. Clin Chem 1998;44:1008-13.
99. Lippi G, Salvagno GL, Montagnana M, Schena F, Ballestrieri F, Guidi GC. Influence of physical exercise and relationship with biochemical variables of NT-pro-brain natriuretic peptide and ischemia modified albumin. Clin Chim Acta 2006;367:175-80.
100. Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003;338:107-15.
101. Sokoll LJ, Baum H, Collinson PO, Gurr E, Haass M, Luthe H, et al. Multicenter analytical performance evaluation of the Elecsys proBNP assay. Clin Chem Lab Med 2004;42:965-72.
102. Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M. Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino-terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med 2004;42:942-4.
103. Buckley MG, Marcus NJ, Yacoub MH. Cardiac peptide stability, aprotinin and room temperature: importance for assessing cardiac function in clinical practice. Clin Sci 1999;97:689-95.
104. Plebani M. Proteomics: the next revolution in laboratory medicine? Clin Chim Acta 2005;357:113-22.
105. Banks RE, Stanley AJ, Cairns DA, Barrett JH, Clarke P, Thompson D, et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 2005;51:1637-49.
106. Karsan A, Eigl BJ, Flibotte S. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin Chem 2005;51:1525-8.
107. Rai AJ, Vitzthum F. Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert Rev Proteomics 2006;3:409-26.
108. Rodriguez-Mendizabal M, Lucena MI, Cabello MR, Blanco E, Lopez-Rodriguez B, Sanchez de la Cuesta F. Variations in blood levels of aminoglycosides related to in vitro anticoagulant usage. Ther Drug Monit 1998;20:88-91.
109. Shaw LM, Bowers L, Demers L, Freeman D, Moyer T, Sanghvi A, et al. Critical issues in cyclosporine monitoring: report of the task force on cyclosporine monitoring. Clin Chem 1987;33:1269-88.
110. Warner A, Privitera M, Bates D. Standards of laboratory practice: antiepileptic drug monitoring. Clin Chem 1998;44:1085-95.
111. Valdes R Jr, Jortani SA, Gheorghiade M. Standards of laboratory practice: cardiac drug monitoring. Clin Chem 1998;44:1096-109.
112. Eriksson T, Holmgren B. Rapid degradation of 3,4-dihydroxyphenylalanine in plasma containing EDTA. Clin Chim Acta 1995;238:209-16.
113. Narayanan S. Preanalytical and analytical pitfalls in molecular biology techniques. J Clin Ligand Assay 1997;20:200-5.
114. Todd DM, Buccini FJ. Apparent heparin interference with restriction enzyme digestion of genomic DNA. Clin Chem 1993;39:362-3.
115. Coad JE, Lander TA, Litz CE. Inhibition of restriction endonucleases by common clinical anticoagulants. Anal Biochem 1992;205:368-9.
116. Dickover RE, Herman SA, Saddiq K, Wafer D, Dillon M, Bryson YJ. Optimization of specimen-handling procedures for accurate quantitation of levels of human immunodeficiency virus RNA in plasma by reverse transcriptase PCR. J Clin Microbiol 1998;36:1070-3.
117. Tsui NB, Ng EK, Lo YM. Stability of endogenous and added RNA in blood specimens, serum and plasma. Clin Chem 2002;48:1647-53.
118. Giordano M, Kelleher T, Colonno RJ, Lazzarin A, Squires K. The effects of the Roche Amplicor HIV1 Monitor ultrasensitive test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons. J Clin Virol 2006;35:420-5.
119. Isaksson HS, Nilsson TK. Preanalytical aspects of quantification TaqMan real time RT-PCR: applications for TF and VEGF mRNA quantification. Clin Biochem 2006;39:373-7.
120. Grant PR, Kitchen A, Barbara JA, Hewitt P, Sims CM, Garson JA, et al. Effects of handling and storage of blood on the stability of hepatitis C virus RNA: implications for NAT testing in transfusion practice. Vox Sang 2000;78:137-42
121. Lee TH, Montalvo L, Chrebtow V, Busch MP. Quantification of genomic DNA in plasma and serum samples: higher concentration of genomic DNA found in serum than in plasma. Transfusion 2001;41:276-82.
122. Davidson DF. Effects of contamination of blood specimens with liquid potassium-EDTA anticoagulant. Ann Clin Biochem 2002;39:273-80.
123. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in incidence of coronary heart disease. J Am Med Assoc 1984;251:351-64.
124. Cooper GR, Myers GL, Smith SJ, Sampson EJ. Standardization of lipid, lipoprotein, and apolipoprotein measurements. Clin Chem 1988;34:B95-105.
125. Beheshti I, Wessels LM, Eckfeldt JH. EDTA-plasma vs. serum differences in cholesterol, high-density-lipoprotein cholesterol, and triglyceride as measured by several methods. Clin Chem 1994;40:2088-92.
126. Willems HP, Bos GM, Gerrits WB, den Heijer M, Vloet S, Blom HJ. Acidic citrate stabilizes blood samples for assays of total homocysteine. Clin Chem 1998;44:342-5.
127. Caliskan S, Kuralay F, Onvural B. Effects of anticoagulants on plasma homocysteine determination. Clin Chim Acta 2001;309:53-6.
128. Salazar JF, Herbeth B, Siest G, Leroy R. Stability of blood homocysteine and other thiols: EDTA or acidic citrate. Clin Chem 1999;45:2016-9.
129. Chuang CK, Lin SP, Lin YT, Huang FY. Effects of anticoagulants in amino acid analysis: comparison of heparin, EDTA, and sodium citrate in Vacutainer tubes for plasma preparation. Clin Chem 1998;44:1052-6.
130. Simon E, Paul JL, Soni T, Simon A, Moatti N. Plasma and erythrocyte vitamin E content in asymptomatic hypercholesterolemic subjects. Clin Chem 1997;43:285-9.
131. Gross MD, Prouty CB, Jacobs DR Jr. Stability of carotenoids and a-tocopherol during blood collection and processing procedures. Clin Chem 1995;41:943-4.
132. Dufaux B, Heine O, Kothe A, Prinz U, Rost R. Blood glutathione status following distance running. Int J Sports Med 1997;18:89-93.
133. Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P. Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem 1997;43:1209-14.
134. Smith DR, Ilustre RP, Osterloh JD. Methodological consideration for the accurate determination of lead in human plasma and serum. Am J Ind Med 1998;33:430-8.
135. Horsti J. Use of EDTA samples for prothrombin time measurement in patients receiving oral anticoagulants. Haematologica 2001;86:851-5.
136. Menssen HD, Brandt N, Leben R, Muller F, Thiel E, Melber K. Measurement of haematological, clinical chemistry, and infection parameters from hirudinized blood collected in universal blood sampling tubes. Semin Thromb Hemost 2001;27:349-56.
137. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990;29:7095-101.
138. Matsuo T, Kario K, Kodama K, Okamoto S. Clinical application of the synthetic thrombin inhibitor Argatroban (MD805). Semin Thromb Hemost 1992;18:155-60.
139. Kumura T, Hino M, Yamane T, Tominaga K, Tatsumi N. DX-9065a, a specific factor Xa inhibitor, as a universal anticoagulant for blood collection tubes. Clin Chim Acta 2000;294:27-35.
140. Lyon ME, Fine JS, Henderson PJ, Lyon AW. PPACK: alternative anticoagulant to heparin salts for blood gas and electrolyte specimens. Clin Chem 1995;41:1038-41.
141. Lyon AW, Harding SR, Drobot D, Lyon ME. Use of thrombin inhibitors ex vivo allows critical care clinical chemistry and hematology testing on common specimens. Clin Biochem 1997;30:121-7.
142. Kinoshita Y, Ohta K, Yamane T, Hino M, Takubo T, Samori T, et al. Synthetic polymer sulphonated polyisoprene as a universal anticoagulant for laboratory testing. J Clin Lab Anal 2000;14:180-7.